Seer Inc. (SEER)

$1.78

-0.03

(-1.66%)

Live

Insights on Seer Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.17M → 3.06M (in $), with an average decrease of 26.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -17.79M → -20.67M (in $), with an average decrease of 16.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 79.2% return, outperforming this stock by 137.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.5% return, outperforming this stock by 331.7%

Performance

  • $1.75
    $1.84
    $1.78
    downward going graph

    1.97%

    Downside

    Day's Volatility :5.16%

    Upside

    3.26%

    downward going graph
  • $1.46
    $5.65
    $1.78
    downward going graph

    17.98%

    Downside

    52 Weeks Volatility :74.16%

    Upside

    68.5%

    downward going graph

Returns

PeriodSeer Inc.Sector (Health Care)Index (Russel 2000)
3 Months
0.56%
0.0%
0.0%
6 Months
-3.72%
7.8%
0.0%
1 Year
-58.2%
12.1%
0.0%
3 Years
-94.21%
17.1%
-24.0%

Highlights

Market Capitalization
122.7M
Book Value
$5.91
Earnings Per Share (EPS)
-1.29
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-821.66%
Return On Assets TTM
-14.14%
Return On Equity TTM
-20.33%
Revenue TTM
15.7M
Revenue Per Share TTM
0.24
Quarterly Revenue Growth YOY
-24.4%
Gross Profit TTM
7.1M
EBITDA
-95.4M
Diluted Eps TTM
-1.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.28
EPS Estimate Next Year
-1.3
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Seer Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 293.26%

Current $1.78
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Seer Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Seer Inc.
Seer Inc.
-16.2%
-3.72%
-58.2%
-94.21%
-96.79%
Moderna, Inc.
Moderna, Inc.
13.18%
69.13%
15.22%
-29.98%
843.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.26%
17.19%
33.13%
94.15%
236.31%
Novo Nordisk A/s
Novo Nordisk A/s
7.2%
45.4%
79.15%
237.53%
459.22%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.77%
17.81%
40.49%
145.91%
181.42%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Seer Inc.
Seer Inc.
NA
NA
NA
-1.28
-0.2
-0.14
NA
5.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.37
30.37
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.74
49.74
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.88
30.88
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Seer Inc.
Seer Inc.
Buy
$122.7M
-96.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$56.6B
843.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.2B
236.31%
30.37
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$638.1B
459.22%
49.74
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.8B
181.42%
30.88
39.46%

Institutional Holdings

  • BlackRock Inc

    8.70%
  • SoftBank Group Corp

    7.91%
  • Artal Group S A

    7.31%
  • Vanguard Group Inc

    4.06%
  • Capital World Investors

    3.17%
  • Acadian Asset Management LLC

    2.05%

Company Information

seer, inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. the company develops proteograph product suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. it intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. seer, inc. has a collaboration program agreement with discovery life sciences, llc; and commercial agreements with bruker scientific llc and thermo electron north america llc. the company was formerly known as seer biosciences, inc. and changed its name to seer, inc. in july 2018. seer, inc. was incorporated in 2017 and is headquartered in redwood

Organization
Seer Inc.
Employees
147
CEO
Dr. Omid C. Farokhzad M.D., Ph.D.
Industry
Technology

FAQs